Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of DYNE-251 Administered Intravenously in Ambulatory Male Participants 4 to 18 Years of Age With Duchenne Muscular Dystrophy Amenable to Exon-51 Skipping

NCT07608432 is registered in ClinicalTrials.gov with Dyne Therapeutics as lead sponsor.

NCT NCT07608432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07608432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of DYNE-251 Administered Intravenously in Ambulatory Male Participants 4 to 18 Years of Age With Duchenne Muscular Dystrophy Amenable to Exon-51 Skipping
Lead sponsor
Dyne Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
June 30, 2026
Completion date
October 31, 2032
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

congenital, hereditary, and neonatal diseases and abnormalities, dmd, duchenne muscular dystrophy (dmd), genetic disease, inborn, genetic disease, x-linked, muscular dystrophies, muscular dystrophies (duchenne, becker, myotonic dystrophy), muscular dystrophy (dmd), muscular dystrophy in children, muscular dystrophy, duchenne, muscular dystrophy, duchenne and becker types, muscular dystrophy, duchenne type, neuromuscular diseases (nmd)